呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02563 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 216,720,857 | RMB | | 1 | RMB | | 216,720,857 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 216,720,857 | RMB | | 1 | RMB | | 216,720,857 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京華昊中天生物醫藥股份有限公司 | 2. 股份分類 | 普通 ...

华昊中天医药-B(02563)发布截至2025年6月30日止六个月中期业绩，营业收入1478.7万元(人民币，下 同)，同比减少55.36%;净亏损5404.1万元，同比收窄23.41%;基本每股亏损0.15元。 ...

Core Insights - The company reported a significant decline in revenue for the six months ending June 30, 2025, with total revenue of 14.787 million RMB, representing a year-on-year decrease of 55.36% [1] - The net loss for the period was 54.041 million RMB, which is a reduction of 23.41% compared to the previous year [1] - The basic loss per share was reported at 0.15 RMB [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 Beijing Biostar Pharmaceuticals Co., Ltd. 北 京 華 昊 中 天 生 物 醫 藥 股 份 有 限 公 司 於中華人民共和國註冊成立的股份有限公司） （股份代號：2563） 中期業績公告 截至2025年6月30日止六個月 北京華昊中天生物醫藥股份有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然公佈本公 司及其附屬公司（ 統稱「本集團」）截至2025年6月30 日止六個月的未經審計綜合中期業績連 同2024年同期的比較數字。該等中期業績並未經核數師審計或審閱，惟已由本公司審計委 員會審閱。 在本公告內，「我們」及「我們的」均指本公司，如文義另有所指，則指本集團。本公告所載 若 干 金 額 及 百 分 比 數 字 已 約 整 或 已 四 捨 五 入 至 小 數 點 後 一 位 或 兩 位 數（ 如 適 用 ）。 任 何 表 格、圖表或其他地方所示總額與所列數額 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 （股份代號：2563） 於2025年8月25日舉行的股東週年大會 投票表決結果 茲提 述北 京華 昊中 天生 物醫 藥股 份有 限公 司（「 本公 司」）日期 均為 2025 年 7 月25 日的 股東 週 年大會通告（「股東週年大會通告」）及通函（「通函」）。除另有指明者外，本公告所用詞彙與 通函所界定者具有相同涵義。 股東週年大會投票表決結果 董 事 會 欣 然 宣 佈 ，於 2025 年 8 月 25 日 舉行 的 股 東 週 年 大 會 上 ， 股 東 週 年大 會 通 告 內 載 列 的 所有普通決議案（「普通決議案」）及一項特別決議案（「特別決議案」，連同普通決議案統稱為 「 該 等 決 議 案」）已 獲 股 東 以 投 票 方 式 正式 通 過 。 於 股 東 週 年 大 會 上 通 過 的 該 等 決 議 案 的 投 票表決結果如下： | | | | | | | | | | | | | | ...

於中華人民共和國註冊成立的股份有限公司） （股份代號：2563） 有關核數師辭任之 補充公告 茲提 述北 京華 昊中 天生 物醫 藥股 份有 限公 司（「 本公 司」）日期 為2025 年7 月 24 日 內容 有關 核 數師辭任的公告（「該公告」）。除另行界定外，本公告所用詞彙與該公告所界定者具有相同 涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 Beijing Biostar Pharmaceuticals Co., Ltd. 北 京 華 昊 中 天 生 物 醫 藥 股 份 有 限 公 司 本公司謹此就大信國際（ 香港 ）會計師事務所有限公司（「大信」）辭任本公司核數師之原因提 供補充資料。 誠如該公告所披露，本公司變更2025財政年度之核數師乃由於本公司決定將編製財務報表 的基準由香港財務報告準則會計準則更改為中國企業會計準則（「中國企業會計準則」（）「變 更」）。鑒於此會計準則變動，本公司董事會（「董事會」）認為不續聘大信為2025財 ...

格隆汇8月14日丨华昊中天医药-B(02563.HK)宣布，本公司将于2025年8月28日（星期四）举行董事会会 议，藉以（其中包括）(i)考虑及酌情批准本公司及其附属公司截至2025年6月30日止六个月的综合中期 业绩及其刊发；(ii)考虑派付中期股息建议（如有）；及(iii)处理任何其他事项。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 Beijing Biostar Pharmaceuticals Co., Ltd. 北京華昊中天生物醫藥股份有限公司 主席兼執行董事 Beijing Biostar Pharmaceuticals Co., Ltd. 北 京 華 昊 中 天 生 物 醫 藥 股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：2563） 董事會會議通告 北京華昊中天生物醫藥股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本 公司將於2025年8月28日（ 星期四 ）舉行董事會會議，藉以（ 其中包括 ）(i)考慮及酌情批准本 公司及其附屬公司截至2025年6月30日止六個月的綜合中期業績及其刊發；(ii)考慮派付中 期股息建議（ 如有）；及(iii)處理任何其他事項。 承董事會命 Tang Li（唐莉）博士 中國北京，2025年8月14日 於本公告日期，董事會成員包括(i)執 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京華昊中天生物醫藥股份有限公司 呈交日期: 2025年8月4日 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02563 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 216,720,857 | RMB | | 1 | RMB | | 216,720,857 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 216,720,857 | RMB | | 1 | RMB | | 216,720,857 | | 2. 股份分類 | 普通股 | 股份類別 | 其他 ...

Financial Performance - Revenue for 2024 reached RMB 71,866,000, representing a 7.9% increase from RMB 66,635,000 in 2023[11] - Gross profit increased to RMB 61,086,000, a 30.5% rise compared to RMB 46,825,000 in the previous year[11] - Pre-tax loss decreased by 24.2% to RMB 143,776,000 from RMB 189,644,000 in 2023[11] - As of December 31, 2024, the company recorded a net loss of RMB 143.8 million, an improvement from a net loss of RMB 189.6 million for the year ended December 31, 2023, primarily due to a sales revenue increase of RMB 5.3 million, representing a growth rate of 7.9%[15] - Other income and net gains decreased by 15.6% to RMB 26.7 million from RMB 31.7 million in 2023, primarily due to reduced realized and unrealized gains from financial assets[69] - Administrative expenses increased by 19.2% to RMB 52.3 million from RMB 43.9 million in 2023, mainly due to increased listing expenses[71] - The company's loss narrowed to RMB 143.8 million for the year ended December 31, 2024, a reduction of RMB 45.8 million from RMB 189.6 million in 2023[74] Research and Development - The core product, Yutide Long injection, received orphan drug designation from the FDA for brain metastasis in breast cancer in March 2024[12] - In July 2024, the FDA approved Yutide Long injection for a key Phase II clinical trial for treating brain metastasis in breast cancer[12] - The company is developing an oral formulation of Yutide Long, which is currently in Phase II/III clinical trials[6] - The company has 19 research and development pipelines, with ongoing clinical trials for Uterodalon targeting new indications such as non-small cell lung cancer and breast cancer brain metastases[21] - The clinical I phase study for Uterodalon capsules was successfully completed in both China and the United States, demonstrating good efficacy and safety, with a focus on late-stage breast cancer treatment[21] - The ongoing clinical trial of Uterol capsules combined with Capecitabine for advanced metastatic breast cancer in China has enrolled 50 patients, with an overall response rate (ORR) exceeding 56.8% and a clinical benefit rate (CBR) of 88.6%[46] - The company is focusing on the development of ADC products using Yutai Dulong as an effective carrier, aiming to enhance its product portfolio and competitiveness[63] Clinical Trials and Approvals - The company has completed enrollment of 2/3 of patients in the Phase III clinical trial for UTD1, with a low incidence of adverse events, indicating good safety[25] - In the Phase II trial for advanced NSCLC, the overall response rate (ORR) was 19.0% and the disease control rate (DCR) was 81.0%, with a median progression-free survival (PFS) of 4.4 months[26] - The ongoing Phase III trial for UTD1 in advanced NSCLC has completed approximately 40% of patient enrollment, with low adverse event rates expected to yield efficacy data by the end of 2025[31] - The key II clinical trial for UTD1 combined with capecitabine for breast cancer brain metastases received IND approval in September 2024, with the first patient enrolled in January 2025[43] - The II clinical study of UTD1 combined with gemcitabine for unresectable advanced pancreatic cancer reported an ORR of 27.27% and a DCR of 72.72%, with a median OS of 9.57 months[43] Intellectual Property and Market Position - The company obtained 17 new PCT patent authorizations in 2024, enhancing its intellectual property protection and solidifying its leading position in the development of innovative anti-tumor drugs[16] - The company has signed a marketing service agreement with Beijing Baiyang Zhihuo Medical Transformation Service Co., Ltd. for exclusive promotion rights of the drug Yutai Dulong starting January 1, 2025, with an upfront payment of RMB 50 million[54] - The company has received multiple PCT patent authorizations for Yutai Dulong, including key patents for its high-yield engineering strains, which are protected until 2041, enhancing the product's barriers to imitation[55] Strategic Partnerships and Global Expansion - The company is actively pursuing strategic partnerships to enhance product commercialization, including a collaboration with Baiyang Pharmaceutical to leverage their market experience and resources[15] - The company plans to deepen its global strategy by accelerating overseas market expansion and advancing multiple global multi-center clinical studies[17] - The company is exploring global partnerships for the co-development and licensing of Yutai Dulong injection and capsules to accelerate international market entry[63] Management and Governance - Qiu Rongguo, the CEO, has over 40 years of experience in the biopharmaceutical field, contributing to the group's overall management and strategic planning since 2002[100] - The company has a strong leadership team with diverse backgrounds in biopharmaceuticals, project management, and financial oversight, enhancing its strategic capabilities[111] - The board includes independent directors with significant expertise in finance and corporate governance, such as Mr. Xiao Shuming and Dr. Ye Chengang[115][117] - The management team is committed to enhancing investor relations and corporate disclosures, led by Mr. Liu Kailin as the company secretary and investment director[125] Corporate Governance and Compliance - The company has complied with all relevant laws and regulations without any significant violations during the reporting period[150] - The auditor issued a qualified opinion on the consolidated financial statements for the year ending December 31, 2024[88] - The company has received annual confirmations of independence from all independent non-executive directors[134] Employee Incentive Plans - The company established three employee stock ownership platforms: Zhuhai Huajin, Zhuhai Huaxin, and Zhuhai Huarong to recognize and incentivize employee contributions[188] - Participants in the employee incentive plans are granted rights to partnership interests in the employee stock ownership platforms upon the award of incentives[191] - The purpose of the employee incentive plans is to enhance the overall competitiveness of the company and ensure the achievement of future business objectives[189]